COVID-19 - Pipeline Insight, 2024

This “COVID-19 - Pipeline Insight, 2024,” report provides comprehensive insights about 400+ companies and 400+ pipeline drugs in COVID-19 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

COVID-19 Understanding

COVID-19: Overview

Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease causes respiratory illness (like the flu) with symptoms such as a cough, fever, and difficulty breathing. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Elderly people and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. The COVID-19 virus is primarily transmitted through droplets of saliva or discharge from the nose when an infected person coughs or sneezes. People can catch COVID-19 if they breathe in droplets from a person with COVID-19 who coughs out or exhales droplets. It also spreads when a person touches a surface or objects that has the virus on it, and then touches their eyes, nose, or mouth.

COVID-19 - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the COVID-19 pipeline landscape is provided which includes the disease overview and COVID-19 treatment guidelines. The assessment part of the report embraces, in depth COVID-19 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, COVID-19 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence COVID-19 R&D. The therapies under development are focused on novel approaches to treat/improve COVID-19.

COVID-19 Emerging Drugs Chapters

This segment of the COVID-19 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

COVID-19 Emerging Drugs

REGN-COV2: Regeneron Pharmaceuticals REGN-COV2 Antibody Cocktail (Casirivimab and Imdevimab; REGN10933 + REGN10987) is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19. To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company's Veloc Immune® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the humanpopulation
Bucillamine: Revive Therapeutics Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC.2 The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other antioxidant and anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19.

Mupadolimab (CPI-006): Corvus Pharmaceuticals Mupadolimab (CPI-006) is an antibody that possesses dual properties: binding to CD73, which may reduce its suppression of the immune response via the adenosine pathway; and activating B cells, which may result in increased antibody production to antigens and the generation of memory B cells to extend protection.

VERU-111: Veru Inc.Sabizabulin is a cytoskeleton disruptor which by causing microtubule depolymerization has both anti-viral and anti-inflammatory activity and could be effective against the SARS-CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to be transported, replicated, assembled, and released from the cell. In addition, microtubule depolymerization drugs that target the “colchicine binding site” of microtubules, like sabizabulin, also have strong anti-inflammatory effects, including the potential to treat the cytokine release syndrome (cytokine storm) and septic shock induced by the SARS-CoV-2 viral infection that is associated with high COVID-19 mortality rates.

Sarconeos (BIO101): Biophytis Sarconeos (BIO101) is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity in various age-related and muscular wastingconditions.

Leronlimab: CytoDyn Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of COVID-19infection.

Tocilizumab: Hoffmann-La Roche Actemra/RoActemra (Tocilizumab) is being developed by Hoffmann-La Roche in phase III stage of development for the treatment of Severe COVID-19 Pneumonia. Actemra/RoActemra is an anti-IL-6 receptor biologic approved to treat moderate-to-severe active rheumatoid arthritis (RA) in adults. The IL-6 protein triggers the body’s immune and inflammatory response to fight infections. But, in the case of those patients where their immune system overreacts, inhibiting IL-6 could keep the body from attackingitself.

In Mar 2020, Roche received Chinese approval for the use of the drug to treat patients developing severe complications from COVID-19.

The new randomized, double-blind, placebo-controlled Phase III trial will be conducted in alliance with the US Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA). It will assess the safety and efficacy of Actemra in combination with standard of care compared to placebo.

COVID-19: Therapeutic Assessment

This segment of the report provides insights about the different COVID-19 drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in COVID-19

There are approx. 400+ key companies which are developing the therapies for COVID-19. The companies which have their COVID-19 drug candidates in the most advanced stage, i.e. phase III include, Regeneron Pharmaceuticals.

Phases

This report covers around 400+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

COVID-19 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Injection
• Intradermal
• Intramuscular
• Intramuscular/intradermal
• Intranasal
• Intranasal/Intramuscular
• Intranasal/Intravenous
• Intraperitoneal
• Intratracheal
• Intravascular
• Intravenous
• Intravenous/subcutaneous
• Oral
• Oral / Enteral
• Oral and Intravenous
• Oral/nasogastric tube
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Subcutaneous/Sublingual
• Sublingual
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Others
• Peptide
• Protein
• Small Molecule
• Stem Cell Therapy
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

COVID-19: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses COVID-19 therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 drugs.

COVID-19 Report Insights

• COVID-19 Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

COVID-19 Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing COVID-19 drugs?
• How many COVID-19 drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of COVID-19?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the COVID-19 therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for COVID-19 and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
• TC BioPharm
• Syntax for Science, S.L
• Shaperon
• Renibus Therapeutics
• Quercis Pharma
• Pharmenterprises
• Pharmamel S.L.
• Orpheris
• OPKO Health
• Oncotelic Inc.
• Notitia Biotechnologies Company
• Jazz Pharmaceuticals
• Ionis Pharmaceuticals
• Inotrem
• Grifols Therapeutics LLC
• Grifols Therapeutics LLC
• Grifols Therapeutics
• Grifols Therapeutics
• Globavir Biosciences
• Genentech, Inc.
• FSD Pharma
• Faron Pharmaceuticals
• Evergreen Therapeutics
• Enlivex Therapeutics
• Eiger BioPharmaceuticals
• Direct Biologics
• Debiopharm
• Clene Nanomedicine
• Chiesi Farmaceutici S.p.A.
• Cadila Healthcare Limited
• Biotest
• BeiGene
• Apeiron Biologics
• AgelessRx
• AbbVie/Apotex
• Telios Pharmaceuticals
• Rapa Therapeutics
• Organicell Regenerative Medicine
• Miltenyi Biomedicine
• Med RegenLLC
• Kiadis Pharma
• Kamada
• Cellularity Incorporated
• Bio-Thera Solutions
• 3M
• Sironax
• Pfizer
• Oncovir
• Ology Bioservices
• Neutrolis
• Neo ImmuneTech
• Natureceuticals Sdn Bhd
• Medicine Invention
• Kiadis Pharma
• Grand Medical
• Frontier Biotechnologies
• Emergent Biosolutions
• Codagenix
• Cellenkos
• AlloVir
• Bausch Health Americas
• AiCuris
• AgenTus Therapeutics
• 4D Pharma

Key Products

• T3 solution for injection
• TCB008
• Bemiparin
• NuSepin
• RBT-9
• IQC-950AN
• Treamid
• Melatonin
• OP-101
• Rayaldee
• OT-101
• NBT-NM108
• Defibrotide
• ISIS 721744
• Nangibotide
• Alpha1-PI
• Convalescent anti-SARS-CoV-2 MBT Plasma
• GAMUNEX-C
• Prolastin
• GBV 006
• Tenecteplase
• FSD201
• IFN beta-1a
• EG-HPCP-03a
• Allocetra-OTS
• Pegylated interferon lambda
• DB-001
• Alisporivir
• CNM-ZnAg
• Poractant alfa (Curosurf)
• Pegylated Interferon-a2b
• Trimodulin
• BGB-DXP593
• APN01
• Naltrexone
• Interferon beta-1a
• TL-895
• RAPA-501
• Organicell Flow
• IMP
• MRG-001
• KDS-1000
• Kamada Anti-SARS-CoV-2
• CYNK-001
• BAT2020
• Povidine iodine nasal swabs
• SIR1-365
• PF-07304814
• Poly-ICLC
• ADM03820
• NTR-441
• NT-I7
• Nuvastatic
• COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection
• K-NK-ID101
• STC3141
• FB2001
• COVID-HIGIV
• COVI-VAC
• CK0802
• Partially HLA-matched SARS-CoVSTs
• Virazole
• AIC649
• agenT-797
• MRx-4DP0004
• Vaxcelerate

This product will be delivered within 2 business days.